Pertuzumab / Trastuzumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), NYE METODER (Norway) and SMC (Scotland), among others, recommended or restricted pertuzumab / trastuzumab, while HAS (France) did not recommend it.
Assessment has run over 5.5 years, from 24 Mar 2021 at HAS (France) to 29 Sep 2026 at TLV (Sweden).
AOTMIT (Poland) changed its position: restricted on 3 Dec 2021, not recommended by 8 Sep 2023.
No assessment is on file from PBAC (Australia), AWMSG (Wales) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 7 of 13 records date from 2023 or later.
HAS (France) was first to assess pertuzumab / trastuzumab, on 24 Mar 2021; TLV (Sweden) did not open a file until 29 Sep 2026 — a wide spread of 5.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 13 dated records fall in 2021 alone.
3 of the 7 agencies here assessed pertuzumab / trastuzumab more than once, PHARMAC (New Zealand) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for pertuzumab / trastuzumab.
The full ledger for pertuzumab / trastuzumab reads 6 recommended, 3 not recommended, 2 restricted and 2 no benefit.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 21 Sep 2026 | Adjuvant treatment of individuals with HER2-positive early breast cancer at high risk of recurrence in combination with … | PTAC advice: Decline | source |
| G-BA (Germany) | 16 Mar 2023 | Phesgo — benefit assessment §35a | added benefit: minor (indication) | source |
| AOTMIT (Poland) | 3 Dec 2021 | programu lekowego „Leczenie chorych na raka piersi (ICD-10 C50) | recommended conditionally | source |
| NYE METODER (Norway) | 24 Oct 2021 | Kombinasjonsbehandling i faste doser til behandling av tidlig brystkreft og metastatisk brystkreft | introduced | source |
| SMC (Scotland) | 12 Jul 2021 | Early breast cancer (EBC) In combination with chemotherapy in: • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early … | accepted (restricted) | source |
8 further decisions for pertuzumab / trastuzumab, across 5 agencies, are not shown here. They include the most recent record on file, 29 Sep 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 13 decisions for pertuzumab / trastuzumab from 7 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.